RT @darrenohara: Delighted to share some of my post-doc work from my time in Toronto @kalialabs where we (and collabs) identified a druggab…
RT @ShorterLab: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models o…
A new study finds that disrupting the alpha-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Learn how StressMarq's Alpha Synuclein Pre-formed Fibrils were used: https://t.co/ke
🧠 In a recently published @NatureComms article, co-authored by #Cyclica's Carles Corbi Verge, PhD, Computational Scientist, researchers find a potential therapeutic target for neurodegenerative diseases, including #ParkinsonsDisease. https://t.co/M6EWnK4
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
New from #ParkinsonsUK https://t.co/qunWXkUwmn Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease.
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease https://t.co/dMMTOxP0vV
RT @ScienceofPD: Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protei…
🧠🙏 #Parkinson: une nouvekle cible contre cette #neurodégénérescence dopaminergique !! Il s'agit d'un inhibiteur peptidique qui permet de diminuer le taux d'α-synucléine in vitro chez l'humain, in vivo chez le #ver C. elegans et le #rat 🐀 https://t.co/fL3V
RT @ScienceofPD: Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protei…
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. https://t.co/lVjcQUzzZd https://t.co/KGv2wxqM0A
RT @ScienceofPD: Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protei…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @DonnellyCentre: Researchers from @KBI_UHN and @DonnellyCentre identify a protein interaction that contributes to Parkinson’s disease -…
Researchers from @KBI_UHN and @DonnellyCentre identify a protein interaction that contributes to Parkinson’s disease - opening a new avenue for therapeutic development. Read more here -> https://t.co/TDZfhN1gtA
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @fede_albanese: Beyond excited to share this amazing work from @kalialabs in which I contributed published on @NatureComms on mitigation…
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. https://t.co/Oo6CGGrmTB
RT @ScienceofPD: Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protei…
RT @ScienceofPD: Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protei…
RT @fede_albanese: Beyond excited to share this amazing work from @kalialabs in which I contributed published on @NatureComms on mitigation…
RT @ShorterLab: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models o…
Beyond excited to share this amazing work from @kalialabs in which I contributed published on @NatureComms on mitigation of neurodegeneration in PD preclinical models by disrupting the interaction between alpha-syn and CHMP2B.
Researchers at @DonnellyCentre @KrembilRI @UofT perform a high-throughput, proteome-wide peptide screen to identify protein-protein interaction inhibitors of #Parkinsons-associated α-synuclein oligomer levels; Most potent peptide inhibitor disrupts CHMP2B
RT @cell_club: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of P…
RT @ShorterLab: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models o…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @ShorterLab: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models o…
RT @DrValiante: Check out this amazing work from @kalialabs labs here at @KBI_UHN
RT @DrValiante: Check out this amazing work from @kalialabs labs here at @KBI_UHN
RT @DrValiante: Check out this amazing work from @kalialabs labs here at @KBI_UHN
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
RT @medical_xpress: Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d htt…
Researchers identify a potential new therapeutic target in #Parkinson'sdisease @NatureComms https://t.co/hkhmdlPD7d https://t.co/2q0DGJEQWS
RT @cell_club: Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of P…
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease: https://t.co/SGvEnJ7Vnl
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @DrValiante: Check out this amazing work from @kalialabs labs here at @KBI_UHN
Check out this amazing work from @kalialabs labs here at @KBI_UHN
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease https://t.co/xdKnqNRrwy
RT @darrenohara: Delighted to share some of my post-doc work from my time in Toronto @kalialabs where we (and collabs) identified a druggab…
Delighted to share some of my post-doc work from my time in Toronto @kalialabs where we (and collabs) identified a druggable interaction between a-synuclein and CHMP2b which can reduce toxicity in preclinial Parkinson's Disease models https://t.co/9J1Eooa5
RT @NicolaJGI: Exciting work from Philip Kim and @kalialabs with @uoftmdphd @mitchdesnoo as coauthor
Exciting work from Philip Kim and @kalialabs with @uoftmdphd @mitchdesnoo as coauthor
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
RT @kalialabs: In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within…
In collaboration with Philip Kim's lab and colleagues, @kalialabs identified a targetable protein-protein interaction within the ESCRT-III pathway that reduces alpha-synuclein toxicity in preclinical models of #Parkinson's @NatureComms https://t.co/gisLWGJ
Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease https://t.co/aiJBKR41PZ